2024-09-02 - Analysis Report
##  LLY Stock Analysis Report

**Company Overview:** Eli Lilly and Company (LLY) is a leading pharmaceutical company developing and manufacturing medicines for diabetes, oncology, autoimmune diseases, and other conditions.

**Performance:**

1. **Return Rate Comparison:** 

    * **LLY Cumulative Return:** 571.94%
    * **VOO (S&P 500) Cumulative Return:** 89.66%
    * **Performance Difference:** 482.28%
    * **Relative Divergence:** 100.0 (This indicates that LLY's performance is currently at the highest point relative to VOO based on historical data.)

    LLY has significantly outperformed the S&P 500 over the analyzed period, showing a strong track record of growth.

2. **Recent Price Movement:**

    * **Closing Price:** 960.02
    * **5-Day Moving Average:** 950.83
    * **20-Day Moving Average:** 907.01
    * **60-Day Moving Average:** 888.73

    LLY's recent price movement shows a short-term upward trend, with the price above all moving averages. This indicates potential positive momentum.

3. **Technical Indicators:**

    * **RSI:** 78.82 
    * **PPO:** 0.36
    * **Delta_Previous_Relative_Divergence:** 18.98 (+) -  Indicates a short-term upward trend.
    * **Expected Return:** 0.0% -  The expected return is based on the current investment amount and a 5-year projection.

    The technical indicators suggest a potential short-term overbought condition (high RSI), but the positive PPO and Delta_Previous_Relative_Divergence suggest continued upward momentum.

4. **Recent Earnings and Outlook:**

    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-08-08 | 3.29 | 11.30 B$ |
    | 2024-04-30 | 2.49 | 8.77 B$ |
    | 2023-11-02 | -0.06 | 9.50 B$ |
    | 2023-08-08 | 1.96 | 8.31 B$ |
    | 2024-08-08 | 1.96 | 8.31 B$ |

    The most recent earnings report (2024-08-08) shows a positive EPS of 3.29, exceeding the estimated figures. This indicates strong financial performance and positive market sentiment.

**Overall Analysis:**

LLY has shown strong historical performance and continues to demonstrate positive momentum. The recent earnings results were strong, surpassing expectations. While technical indicators suggest a potential overbought situation, the overall picture remains positive. Investors should monitor the stock closely for potential correction, but LLY continues to be a strong investment prospect in the pharmaceutical sector. 
